Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

Francesco Legge; Amelia Paglia; Marco D'Asta; Gilda Fuoco; Giovanni Scambia; Maria Gabriella Ferrandina

doi:10.1186/1471-2407-11-214

Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

Francesco Legge
, Amelia Paglia
, Marco D'Asta
, Gilda Fuoco
, Giovanni Scambia
, Maria Gabriella Ferrandina

Risultato della ricerca: Contributo in rivista › Articolo

32 Citazioni (Scopus)

Abstract

Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.

Lingua originale	Inglese
pagine (da-a)	214-214
Numero di pagine	1
Rivista	BMC Cancer
Volume	11
Numero di pubblicazione	Maggio
DOI	https://doi.org/10.1186/1471-2407-11-214
Stato di pubblicazione	Pubblicato - 2011

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Adult
Aged
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Endostatins
Female
Humans
Middle Aged
Neovascularization
Ovarian Neoplasms
Pathologic
Pyrazoles
Quality of Life
Recurrence
Sulfonamides
Survival Analysis
Treatment Outcome
Vascular Endothelial Growth Factor A

Accesso al documento

10.1186/1471-2407-11-214

Altri file e collegamenti

Open Access link a IRIS PubliCatt

Cita questo

@article{b2510f5316b843ab9ed32e7148cd6af9,

title = "Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients",

abstract = "Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.",

keywords = "Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Endostatins, Female, Humans, Middle Aged, Neovascularization, Ovarian Neoplasms, Pathologic, Pyrazoles, Quality of Life, Recurrence, Sulfonamides, Survival Analysis, Treatment Outcome, Vascular Endothelial Growth Factor A, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Endostatins, Female, Humans, Middle Aged, Neovascularization, Ovarian Neoplasms, Pathologic, Pyrazoles, Quality of Life, Recurrence, Sulfonamides, Survival Analysis, Treatment Outcome, Vascular Endothelial Growth Factor A",

author = "Francesco Legge and Amelia Paglia and Marco D'Asta and Gilda Fuoco and Giovanni Scambia and Ferrandina, \{Maria Gabriella\}",

year = "2011",

doi = "10.1186/1471-2407-11-214",

language = "English",

volume = "11",

pages = "214--214",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central",

number = "Maggio",

}

TY - JOUR

T1 - Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

AU - Legge, Francesco

AU - Paglia, Amelia

AU - D'Asta, Marco

AU - Fuoco, Gilda

AU - Scambia, Giovanni

AU - Ferrandina, Maria Gabriella

PY - 2011

Y1 - 2011

N2 - Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.

AB - Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Endostatins

KW - Female

KW - Humans

KW - Middle Aged

KW - Neovascularization

KW - Ovarian Neoplasms

KW - Pathologic

KW - Pyrazoles

KW - Quality of Life

KW - Recurrence

KW - Sulfonamides

KW - Survival Analysis

KW - Treatment Outcome

KW - Vascular Endothelial Growth Factor A

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Endostatins

KW - Female

KW - Humans

KW - Middle Aged

KW - Neovascularization

KW - Ovarian Neoplasms

KW - Pathologic

KW - Pyrazoles

KW - Quality of Life

KW - Recurrence

KW - Sulfonamides

KW - Survival Analysis

KW - Treatment Outcome

KW - Vascular Endothelial Growth Factor A

UR - https://publicatt.unicatt.it/handle/10807/3721

U2 - 10.1186/1471-2407-11-214

DO - 10.1186/1471-2407-11-214

M3 - Article

SN - 1471-2407

VL - 11

SP - 214

EP - 214

JO - BMC Cancer

JF - BMC Cancer

IS - Maggio

ER -

Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo